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Introduction
Alloimmunisation remains a major problem in 
transfused patients with sickle cell disease (SCD). 
In an effort to reduce alloimmunisation to red blood 
cell (RBC) antigens some programmes have been 
implemented to provide RBC transfusions matched 
for at least Rh and K to patients with SCD who are in 
need of chronic transfusion support1-3. However, it has 
been observed that despite provision of Rh phenotyped 
matched RBC to patients with SCD, these patients 
still produce Rh antibodies4,5 and in many cases the 
antibodies are considered autoantibodies because the 
patient's own RBC type serologically positive for the 
corresponding antigen.
The Rh blood group system is one of the most 
important and complex blood group systems with 
a large number of antigens and is involved in RBC 
alloimmunisation, haemolytic transfusion reactions 
and haemolytic disease of the foetus and newborn6. 
It comprises 54 antigens defined serologically and 
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recognised by the International Society of Blood 
Transfusion (ISBT)7. The most common antigens 
are D, C, c, E and e, defined by commercial reagent 
antibodies. The RH locus on chromosome 1 consists of 
two homologous genes: RHD encoding the D protein and 
RHCE encoding the Ce, ce, cE and CE proteins6,8. As a 
consequence of the homology and opposite orientation 
of the two RH genes, many rearrangements occur 
between these two genes and result in hybrid genes. 
These arrangements are thought to allow "hairpin" 
formation and exchange between the genes (the so-
called gene conversion mechanism). A large number of 
RH variants and low incidence antigens arise from this 
mechanism8,9. Over of 200 RHD alleles and 80 RHCE 
alleles have been reported, and new alleles are still being 
discovered (ISBT10 and Rhesus Site11). Patients with 
partial antigens and/or lacking high prevalence antigens, 
such as hrB and hrS, may develop Rh alloantibodies12. 
The high prevalence of altered RH alleles in Africans 
contributes to the high rate of Rh alloimmunisation in 
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SCD patients5,13. Alloimmunisation to Rh antigens in 
populations of African  origin is complicated by the 
genetic diversity of the RH locus and the limitations of 
serological methods to distinguish the variant antigens5. 
RH genotyping has revealed that many patients with SCD 
carry alleles encoding partial Rh antigens but little clinical 
or biological evidence related to alloimmunisation and 
haemolytic transfusion reactions is available for all the 
RH variant alleles. The identification of alloantibodies 
in patients with SCD carrying RH variants is important 
and a complete characterisation of the variants producing 
alloantibodies is required, because alloantibodies in those 
patients may be confused with autoantibodies. In this 
study, we characterised variant RH alleles in patients 
with SCD who made antibodies to Rh antigens despite 
their antigen-positive status and evaluated the clinical 
significance of the antibodies produced. We demonstrated 
that 65% of the patients with SCD alloimmunised to Rh 
antigens carried RH variant alleles and that 42% of the 
antibodies encountered had clinical significance. 
Material and methods
Patients' samples
We studied DNA samples from 48 African Brazilian 
patients with SCD (homozygous for haemoglobin S) who 
had been multiply transfused and were receiving RBC units 
antigen-matched for RhD, C, E, c, e and K, and made one or 
more antibodies with Rh specificities. All patients agreed to 
participate in this study by signing an Institutional Review 
Board-approved informed consent form. 
Serology
RBC from of all alloimmunised patients were typed 
for D, C, c, E and e by haemagglutination in gel cards 
(Bio-Rad, Cressier sur Morat, Switzerland) using two 
different commercial sources of anti-sera (Immucor, 
Norcross, GA, USA; Bio-Rad). An indirect antiglobulin 
test was used to screen for and identify antibodies. A 
direct antiglobulin test and autologous control were 
performed in gel for all samples antigen-positive for the 
corresponding Rh antibody specificity. Eluate studies 
were performed on all samples with a positive direct 
antiglobulin test using an acid elution method (DiaCidel, 
Bio-Rad). Adsorption onto autologous RBC was also 
performed to aid the differentiation of autoantibodies 
and alloantibodies. 
DNA preparation
Genomic DNA was extracted from whole blood by 
a manual spin column separation technique (QIAmp, 
Qiagen, Valencia, California, USA), according to the 
manufacturer's instructions. The concentration of the DNA 
was measured with a NanoDrop 2000c spectrophotometer 
(Thermo Scientific, Waltham, MA, USA). 
DNA array analysis
DNA array analysis was performed using 
wRHCE and wRHD BeadChips from BioArray 
Solutions (Immucor, Warren, NJ, USA) containing 
34 markers associated with altered RhD expression 
and 25 polymorphisms associated with altered 
RHCE alleles. It should be noted that wRHD and 
wRHCE BeadChips devices are for "research use 
only" to date. The two assays were performed with 
8 mL of each DNA sample, containing ~10 to 80 ng/μL 
of genomic DNA for wRHD and ~10 ng/μL for wRHCE, 
according to the manufacturer's recommendations. The 
polymerase chain reactions (PCR) were performed 
in a Veriti thermal cycler (Life Technologies) and 
BeadChips carriers containing single-stranded 
amplicons and an elongation mixture were incubated at 
53 °C in a high humidity hybridisation oven ([Boekel 
InSlide-Out, model 241000], Boekel, Feasterville, PA, 
USA). The fluorescence of each bead was analysed 
on the Bioarray Solutions® Array Imaging System to 
determine positive and negative reactions. BioArray 
Solutions Information System (BASIS) software was 
used to calculate the adjusted intensity of every reaction 
to assign a genotype and predicted phenotype. 
DNA sequence analysis
 DNA sequence analysis was performed on PCR 
products amplified from  genomic DNA in all samples that 
were not characterized by the RHD and RHCE BeadChips 
in order to determine the specific allele present using RHD 
and RHCE specific primers as previously reported13,14. 
PCR products were purified by elution from 1% agarose 
gels using a Qiaex II gel extraction kit (Qiagen, Valencia, 
CA, USA), and sequenced directly, without subcloning, 
on an ABI 373XL Perkin Elmer Biosystems sequencer, 
with the Perkin Elmer Biosystems Big Dye reagent BD 
Half-term (GenPak, Perkin Elmer Biosystems, Foster 
City, CA, USA).
 In order to determine RH allelic combinations on 
samples identified with RHCE variants, we performed 
Rh-cDNA cloning and sequencing. RNA was isolated 
from reticulocytes with TriZol (Invitrogen, Carlsbad, 
CA, USA). Reverse transcription was carried out with 
Superscript First Strand Synthesis (Invitrogen, Carlsbad, 
CA, USA) using gene-specific primers. PCR products 
amplified from cDNA were purified with ExoSAP-IT 
(USB, Cleveland, OH, USA), cloned into a TA vector 
(Invitrogen, Carlsbad, CA, USA) and sequenced using 
previously reported primers15.
Determination of RHD zygosity
For specific detection of the RHD gene deletion we 
used a PCR-restriction fragment length polymorphism 
(amplification of the downstream and hybrid Rhesus 
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box as well as digestion of the PCR products with the 
restriction enzyme Pst I) as previously reported16. We 
also used a quantitative PCR approach17 complemented 
by the specific detection of RHDΨ18.
Analysis of Rh immunisation
Records of transfusions, serological and molecular 
features in all antigen-positive patients with 
corresponding antibodies were analysed. The clinical 
significance of the antibodies was evaluated by 
retrospective analysis of the haemoglobin (Hb) levels 
before and after transfusion and determined by changes 
from the patient's baseline values calculated as the mean 
pre-transfusion percentage of HbS and Hb levels at the 
time of antibody detection. 
Results
Serology
Among the 48 SCD patients with Rh antibodies 
studied, nine were antigen-negative for the corresponding 
antibody specificity (3 anti-D in D-negative patients 
and 6 anti-C in C-negative patients) and 39 were 
antigen-positive with 4+ or weak agglutination 
reactions (15 anti-D whose RBC typed D-positive; 16 
anti-e whose RBC typed e-positive; 4 anti-C whose 
RBC typed C-positive; 2 anti-D,-e whose RBC typed 
positive for both D and e; and 2 anti-D,-C whose RBC 
typed positive for both D and C). Autologous controls, 
the direct antiglobulin test and eluate were positive in 
8/39 (20.5%) patients whose RBC typed serologically 
positive for the corresponding antibody. Adsorption 
Table I  - RH genotypes and predicted phenotypes in 39 SCD patients with Rh antibodies whose RBC typed positive for the 
corresponding antigen.
N. RH Genotypes and Predicted Phenotypes
D+ patients with anti-D considered to be alloantibodies
Genotypes* Predicted phenotypes
3 DIIIa-ceS/DIIIa-ceS partial D, C−E−, partial c, partial e
3 DAR-ce/DAR-ceAR partial D, C−E−c+e+
1 DAR-ce/ceEK partial D, C−E−c+e+
2 DAU0-ce/D–ce partial D, C−E−c+e+
1 DAU3-cE/DAU5-ce partial D, C−E+c+e+
1 DAU4-ce48C/DAU4-ce48C partial D, C−E−c+e+weak
3 Weak partial 4.0-ce733G/weak partial 4.0-ce733G partial D, C−E−, partial c, partial e
1 Weak partial 4.0-ce/DIIIa-CE(4-7)-D-ceS partial D, partial C, E−c+e+
e+ patients with anti-e considered to be autoantibodies
Genotypes Predicted phenotypes
5 D-ce/D-ce D+C−E−c+e+
1 D-Ce/ce D+C+E−c+e+
2 D-cE/ce D+C−E+c+e+
e+ patients with anti-e considered to be alloantibodies
Genotypes Predicted phenotypes
2 D-Ce/D-ce48C,733G D+C+E−, partial c, partial e
3 ceS/ce733G D−C−E−, partial c, partial e
2 D-ce48C/D-ceS D+C−E−c+, partial e
1 ce48C,733G/ce733G D−C−E−, partial c, partial e
D+ and e+ patients with anti-D and anti-e considered to be alloantibodies
Genotypes Predicted phenotypes
1 DAR-ceS/DAR-ceAR partial D, C−E−, partial c, partial e
1 DAU5-ce48C/DAU0-ceMO partial D, C−E−, partial e
C+ patients with anti-C considered to be alloantibodies
Genotypes Predicted phenotypes
1 DIIIa-CE(4-7)-D-ceS/DAU0-ce partial D, partial C, E−c+e+
3 DIIIa-CE(4-7)-D-ceS/ DIVa-2-ceTI partial D, partial C, E−c+, partial e
D+ and C+patients with anti-D and anti-C considered to be alloantibodies
Genotypes Predicted phenotypes
2 DIIIa-CE(4-7)-D-ceS/ DIVa-2-ceTI partial D, partial C, E−c+, partial e
* The order of the two alleles within the RH genotypes is arbitrary and does not correspond to the presumed haplotype.
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onto autologous RBs showed that these eight patients 
had autoantibodies.
Molecular analyses
Molecular analyses revealed RHD and RHCE alleles 
associated with variant D, C and e antigens in 31/48 (65%) 
of SCD patients with Rh antibodies (Table I). Except for 
RHD*DAU0, found in three samples by sequencing, the 
other RH variants were identified by wRHD and wRHCE 
BeadChips. Homozygous, heterozygous and compound 
heterozygous alleles were found by cDNA analysis. Allelic 
associations showed that five patients (2 with anti-D, -e; 
1 with anti-C and 2 with anti-D, -C) were compound 
heterozygotes for RHD and RHCE variants (Table I).  
Rh immunisation
All 39 patients with "unexplained" Rh antibodies 
had received ten or more units of RBC cells within 
the preceding 6 months. Autologous adsorption results 
associated with molecular findings of RH variants in 31 
patients showed that eight patients had autoantibodies and 
31 had alloantibodies. Retrospective analysis showed that 
13/31 alloantibodies (4 anti-D, 5 anti-e and 4 anti-C) were 
involved in delayed haemolytic transfusion reactions or 
decreased survival of transfused RBC as verified by the 
change from the patients' baseline pre-transfusion Hb 
and percentage of HbS at the time of antibody detection. 
Those antibodies were associated with worsened anaemia 
and/or an increase in HbS (Table II). 
Discussion
In our institution matching in patients with SCD 
includes, in addition to ABO, phenotyping for Rh, K1, 
Fya, Jka, S and Dia prior to RBC transfusion, with the aim 
of preventing alloimmunisation to these RBC antigens 
and as part of the antibody identification process. In this 
study, we performed RH genotyping in 48 patients with 
SCD immunised to Rh antigens to determine RH variants 
and evaluated the clinical significance of the antibodies 
by change in Hb levels at the time of antibody detection. 
We report here variant RH alleles associated with 
Rh alloimmunisation in 31/48 of African Brazilian 
patients with SCD. RHD variants were found in 
23/31 patients, RHCE variants in 28/31 and RHD and 
RHCE allele combinations in 20/31 patients. The most 
frequent RHD alleles found in our group of patients 
were RHD*DAR, RHD*weak partial 4.0, RHD*DIIIa 
and RHD*DAU0. With regards to RHCE alleles carried 
by these SCD patients, the most frequent alleles were 
RHCE*ceS, RHCE*ce48, RHCE*ce733G, RHCE*ceAR 
and RHCE*ceTI. Variant RHD alleles were present in 
the homozygous and in the heterozygous state in 44% 
of cases and in the hemizygous state in 12% of patients. 
Variant RHCE alleles were found in the homozygous 
state in 25% of cases, in compound heterozygosity in 
43% and in heterozygosity with a conventional allele 
in 29% of patients.
The RH variants characterised herein have already 
been associated with Rh alloimmunisation in SCD 
patients5,12,13,19. The main difference in this study is 
the inclusion of patients with Rh antibodies only. The 
majority of patients had single Rh antibodies although 
four (13%) had more than one Rh antibody. In 31 cases, 
antibodies occurred in patients whose RBC were positive 
for the antigen and were associated with Rh variants by 
RH genotyping. Thirteen of the Rh antibodies associated 
Table II  - RH genotypes found in 13 patients with SCD associated with clinically significant antibodies involved in decreased 
survival of transfused RBC.
ID Antibody specificity*
RH genotype RBC 
transfusions 
Haemoglobin S (%)
at antibody detection
Haemoglobin (g/dL)
at antibody detection
N. Pre-transfusion
Post-
transfusion
Pre-
transfusion
Post-
transfusion
375 Anti-e ceS/ce733G 64 23.8 45.8 7.8 6.9
509 Anti-e ceS/ce733G 38 24.3 58.1 8.5 6.4
510 Anti-e D-ce48C/D-ceS 142 29.6 42.1 9.8 8.1
516 Anti-e ceS/ce733G 94 25.3 40.8 8.9 7.5
517 Anti-e ce48C,733G/ce733G 18 28.9 46.1 9.5 8.2
534 Anti-D DIIIa-ceS/DIIIa-ceS 103 19.6 44.6 8.4 7.2
536 Anti-D DIIIa-ceS/DIIIa-ceS 32 29.3 47.2 9.0 7.8
538 Anti-D DAR-ce/DAR-ceAR 14 26.1 34.6 7.9 6.8
562 Anti-D DAU4-ce48C/DAU4-ce48C 16 23.1 43.6 8.6 8.0
711 Anti-C DIIIa-CE(4-7)-D-ceS/ DIVa-2-ceTI 84 24.1 45.3 7.9 6.8
722 Anti-C DIIIa-CE(4-7)-D-ceS/ DIVa-2-ceTI 114 44.3 54.8 6.9 5.9
738 Anti-C DIIIa-CE(4-7)-D-ceS/ DIVa-2-ceTI 62 27.6 58.1 8.6 7.6
752 Anti-C DIIIa-CE(4-7)-D-ceS/DAU0-ce 321 26.4 50.7 7.3 6.5
* Rh antibodies considered to be alloantibodies. RBC: red blood cells. 
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with altered D, C and e antigens due to homozygous 
or compound heterozygous RHD and RHCE variant 
alleles were found to be clinically significant, as shown 
by a worsened anaemia and/or increase in HbS when 
the patients were transfused with the corresponding 
antigens. Patients who are homozygous, hemizygous 
or compound heterozygous for RH alleles therefore 
require a different approach to transfusion management. 
For example, two patients who developed clinically 
significant anti-C had the hybrid DIIIa-CE(4-7)-D that 
encodes a partial C antigen associated with variant RHD 
alleles encoding partial D: for these patients strategies 
to provide D−, C− should be implemented. Although, 
antibodies against high-prevalence antigens, such as 
Hrs (RH18) and HrB (RH34) were not identified in 
our SCD cohort, they have been documented in SCD 
patients with variant RHCE alleles in a homozygous 
state19. It has also been demonstrated by other authors 
that the Rh antibodies produced by patients with some 
of the variants found among our patients or antibodies 
against high-prevalence antigens can be involved in the 
occurrence of delayed haemolytic transfusion reactions 
or deaths5,13.
Furthermore, in patients with SCD there is a strong 
association between autoantibody development and 
alloimmunisation5,12. In this study, the RHCE gene 
analysis together with serological analysis led to the 
prediction of autoantibodies against e antigen in 8/48 
(17%) of the patients, whereas alloantibodies against 
D, C and e antigens were detected in 31/48 (65%). 
Knowledge of the prevalence of RH variants and reports 
such as this one on the clinical significance of antibodies 
produced in individuals carrying such variants support 
the development of strategies to match RH to avoid Rh 
alloimmunisation and the risk of haemolytic transfusion 
reactions and/or poor transfusion outcomes.  
 Molecular Rh typing has been used to identify 
altered RH alleles and to predict whether an antibody 
is an autoantibody or alloantibody and is playing 
an important role in expanding matching of the RH 
system in SCD patients and donors5,8,12. Transfusion 
therapy could be improved in such patients if donor 
centres performed molecular screening in large numbers 
of donors to identify donors with RH variants for 
matching20. As blood group genotyping is becoming 
part of laboratory routine and platforms targeting a large 
number of RH polymorphisms are becoming available 
we believe that molecular analysis of RH variants in 
patients and donors would be feasible. 
In conclusion, we characterised a cohort of SCD 
patients prone to alloimmunisation and delayed 
haemolytic transfusion reactions and demonstrated 
that some variant RH alleles were frequent in these 
patients. With this information, a strategy to prevent 
Rh alloimmunisation can be implemented. Our finding 
reinforces the importance of recognising SCD patients 
with RH variants in order to provide them with Rh 
genetically-matched RBC units.
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